CAMP4 Therapeutics Corporation CAMP 深 滬
等待開盤 04-03 09:30:00 美东时间
4.47
+0.010
+0.22%
華盛通- 最 高4.575
- 今 開4.39
- 成交量 3.80万股
- 最 低 4.3606
- 昨 收 4.46
- 總市值 2.32亿
- 52周最高 7.75
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 1.305
- 委 比 15.61%
- 總股本 5191.93万
- 歷史最高 12.30
- 量 比 0.45
- 振 幅 4.81%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names. See complete view of rating changes, including upgrades/downgrades, on our analyst ratings page.
04-02 23:49
Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9
Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.
04-02 22:50
CAMP4 Appoints Michael MacLean to its Board of Directors
CAMP4 Therapeutics announced the appointment of Michael MacLean to its Board of Directors. With over 35 years of financial and operational leadership in biotechnology, MacLean brings extensive experience in growing innovative biotech companies. His expertise will support CAMP4 as it advances its CMP-002 program toward a Phase 1/2 clinical trial for SYNGAP1-related disorder, for which there are currently no approved treatments. MacLean previously ...
03-24 11:00
美股牛股 | 医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%
医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%，获诺和诺德授权销售其减肥药；QURE大涨26%，FDA疫苗负责人将离职，有分析称监管政策或转向灵活>>
03-10 16:46
CAMP4 to Participate in Upcoming Investor Conferences
CAMP4 Therapeutics Corporation will participate in three upcoming investor conferences: the Leerink Partners Global Healthcare Conference on March 9, 2026, featuring a Fireside Chat in Miami; the Stifel CNS Forum on March 17, 2026, with a virtual Corporate Presentation; and the Needham & Company 25th Annual Healthcare Conference on April 13, 2026, also a virtual Corporate Presentation. Webcasts and replays are available on CAMP4’s investor relati...
03-06 21:05
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress
CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an announcement. On March...
03-06 05:37
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics announced advancements in their SYNGAP1 program, including ongoing GLP toxicology studies for CMP-002 and plans to initiate a global Phase 1/2 clinical trial by mid-2026. The company entered a strategic collaboration with GSK to develop RNA-based therapeutics, receiving $17.5 million upfront and potential milestone payments. Additionally, CAMP4 completed a $50 million private placement and a $30 million stock offering, extendin...
03-05 21:05
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics Corporation granted a non-qualified stock option for 8,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4). The option has a 10-year term and an exercise price of $5.78, vesting over four years with 25% after one year and the remainder in monthly installments. CAMP4 focuses on RNA-targeting therapeutics to address genetic diseases by amplifying healthy protein levels.
01-16 21:05
CAMP4 Therapeutics updates corporate investor presentation materials
An announcement from CAMP4 Therapeutics Corporation ( ($CAMP) ) is now availabl...
01-10 06:04
CAMP4 Therapeutics Prices $30M Underwritten Offering Of 5M Shares At $6.00 Each
CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression
2025-12-18 20:11
